DC
TVRD

Davenport & Co’s Tvardi Therapeutics TVRD Stock Holding History

Davenport & Co’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-305
Closed -$136K – 719
2018
Q1 		$136K Sell
305
-71
-19% -$34.4K ﹤0.01% 661
2017
Q4 		$166K Sell
376
-16
-4% -$7.29K ﹤0.01% 662
2017
Q3 		$193K Sell
392
-628
-62% -$314K ﹤0.01% 632
2017
Q2 		$565K Buy
1,020
+416
+69% +$264K 0.01% 405
2017
Q1 		$202K Hold
604
– – ﹤0.01% 584
2016
Q4 		$201K Buy
604
+10
+2% +$3.21K ﹤0.01% 587
2016
Q3 		$178K Buy
+594
New +$129K ﹤0.01% 582

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Davenport & Co's TVRD Position: Q2 2018 in Review

Davenport & Co sold out of Tvardi Therapeutics (TVRD) in Q2 2018, closing a stake of 305 shares — an estimated $136K sold.

Davenport & Co first reported a position in TVRD in Q3 2016 and held it in 7 quarters. The position peaked at $565K in Q2 2017. 130 funds tracked by Wall St. Rank hold TVRD as of Q2 2018.

  • Davenport & Co reported no remaining Tvardi Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Davenport & Co sold 305 Tvardi Therapeutics shares in Q2 2018, an estimated $136K.
  • Davenport & Co first reported a position in Tvardi Therapeutics in Q3 2016 and held it in 7 quarters.
  • Davenport & Co's Tvardi Therapeutics position peaked at $565K in Q2 2017.
  • 130 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2018.

Based on Davenport & Co's 13F filing for Q2 2018, filed 9 Jul 2018.